title: Ganetespib AIDS lung cancer survival.
abstract: A randomized phase II clinical trial demonstrated that combining the second-generation heat shock protein 90 inhibitor ganetespib with docetaxel can boost overall survival in patients with advanced lung adenocarcinoma who started therapy more than six months after diagnosis.
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D000077143:Docetaxel; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage*; D023041:Xenograft Model Antitumor Assays
chemical_list: D018841:HSP90 Heat-Shock Proteins; C533237:STA 9090; D043823:Taxoids; D014230:Triazoles; D000077143:Docetaxel